OxOnc Development LP announced that it has entered into a co-development
agreement with Pfizer Inc., to conduct a pivotal clinical trial of
Pfizer's crizotinib, marketed under the trademark Xalkori(R), for the
treatment of patients with advanced non-small cell lung cancer (NSCLC)
harboring a ROS1 (c-ros) gene
Showing posts with label NCE. Show all posts
Showing posts with label NCE. Show all posts
Subscribe to:
Posts (Atom)